

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: September 20, 2017	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated September 20, 2017 titled "Zydus receives final approval from the USFDA for Desoximetasone Ointment and Labetalol Hydrochloride Tablets".

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

**Zydus receives final approval from the USFDA
for Desoximetasone Ointment and Labetalol Hydrochloride Tablets**

Ahmedabad, 20 September 2017

Zydus Cadila has received the final approval from the USFDA to market Desoximetasone Ointment USP, 0.25% . Desoximetasone Ointment is used in relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The drug will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group also received the final approval from the USFDA to market Labetalol Hydrochloride Tablets USP in the strengths of 100 mg, 200 mg, and 300 mg. Labetalol Hydrochloride Tablets are used to treat high blood pressure (hypertension). The drug will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad.

The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
